EXICURE, INC. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
EXICURE, INC. (XCUR) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2026-08-14
- EXICURE, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-06-30 was 0.00 shares.
- EXICURE, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- EXICURE, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-06-30 was 0.00 shares.
- EXICURE, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-03-31 was 10.41K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month |
|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-14 | 0.00 shares 10-Q · filed 2026-08-14 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-29 | |
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-14 | 10.35K shares 10-Q · filed 2026-08-14 |
| 2025-03-31 | 10.41K shares 10-Q · filed 2026-05-29 | |
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-08-08 | 0.00 shares 10-Q · filed 2025-08-08 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-06-27 | |
| 2021-03-31 | 0.00 shares 10-Q · filed 2021-05-12 | |
| 2020-03-31 | 1.17M shares 10-Q · filed 2021-05-12 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |